(Q37170758)

18 August 2017

title

Anti-VEGF therapy: comparison of current and future agents (English)

1 reference

18 August 2017

D J Pieramici

1

1 reference

18 August 2017

M D Rabena

series ordinal

2

1 reference

18 August 2017

publication date

23 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

22

1 reference

18 August 2017

issue

10

1 reference

18 August 2017

page(s)

1330-1336

1 reference

Tumor angiogenesis: therapeutic implications

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

Pharmacokinetics of intravitreal ranibizumab (Lucentis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

Transplacental carcinogenesis by stilbestrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

inferred from DOI database lookup

7 January 2021

based on heuristic

Vascular permeability factor, an endothelial cell mitogen related to PDGF

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

inferred from DOI database lookup

7 January 2021

based on heuristic

Pharmacokinetics of intravitreal bevacizumab (Avastin)

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.88

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/EYE.2008.88

1 reference

18 August 2017

1 reference